On the relationship between plasma concentrations of drugs and outcome of stroke studies in laboratory animals

Annals of the New York Academy of Sciences

Volumn 939, Issue , 2001, Pages 297-308

  Curry, Stephen H ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b NONE   (United States)

Author keywords

Laboratory animals; Pharmacokinetics; Plasma concentration; Stroke studies

Indexed keywords

AR R 15896; LANICEMINE; MALONIC ACID; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

BRAIN HEMORRHAGE; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG PENETRATION; GERBIL; MARMOSET; MEDICAL RESEARCH; METHODOLOGY; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PROBLEM SOLVING; STROKE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034937934     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03637.x     Document Type: Conference Paper

References (10)

1. AR-R15896 AR reduces cerebral infarction volumes after focal ischemia in cats
2. [(S)-alpha-phenyl-2-pyridine-ethenamine dihydrochloride], a low affinity uncompetitive N-methyl-D-aspartic acid antagonist, is effective in rodent models of global and focal ischemia
3. AR-R15896 AR in patients with acute stroke - A dose finding study
4. AR-L15896, a novel N-methyl-D-aspartate receptor ion channel antagonist: Neuroprotection against mitochondrial metabolic toxicity and regional pharmacology
5. [S]-AR-R15896AR - A novel anticonvulsant: Acute safety, pharmacokinetic and pharmacodynamic properties
6. Efficacy of AR-R15896 AR in the rat monofilament model of transient middle cerebral artery occlusion
7. AR-R 15896 AR, a low affinity, use dependent, NMDA antagonist, is neuroprotective in a primate model of stroke
8. The low-affinity, use-dependent NMDA receptor antagonist AR-R15896 AR: An update of progress in stroke
9. Low-affinity NMDA receptor antagonists: The neuroprotective potential of ARL15896 AR
10. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients. A dose-ranging study